Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

CAR-T Commercialization Strategies: Views From Novartis And Kite

T-cells attacking cancer_1200x675

Related Content

Kite’s Axi-Cel CAR-T: No Adcomm, No Problem

Aug 11 2017

Novartis Begins CAR-T Payment Experiments With Outcomes-Based Contract With CMS

Aug 31 2017

Novartis Woos Payers With Data Showing Entresto Earns Its Keep

Nov 16 2016

Juno Ends JCAR015 Development In ALL, Cementing Third Place CAR-T Position

Mar 02 2017

Cell And Gene Therapies: Where Few Standard Rules Apply

Oct 06 2017

Gilead/Kite Pricing For Yescarta Undercuts Novartis's CAR-T Kymriah

Oct 19 2017

Related Companies

Novartis AG

Kite Pharma, Inc.

Stanford University

Bristol Myers Squibb Company

Anthem Inc.

Cogent Biosciences, Inc.

Bellicum Pharmaceuticals, Inc.

Gilead Sciences, Inc.

Additional Topics

Regenerative Medicine Commercial Innovation Cancer

More from Innovation

More from In Vivo

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window